About RSwitch RSwitch is a proprietary regulatable gene therapy system that enables oral, small molecule drug control of transgene levels in gene and cell therapy applications. RSwitch encodes a ...

The ability to control the expression of therapeutic genes within a “therapeutic window” is crucial to ensure the development of safe and effective gene therapies, but to date, there has been no ...

Just like a doctor adjusts the dose of a medication to the patient's needs, the expression of therapeutic genes, those modified in a person to treat or cure a disease via gene therapy, also needs to ...

CAMBRIDGE, MA -- Many diseases are caused by a missing or defective copy of a single gene. For decades, scientists have been working on gene therapy treatments that could cure such diseases by ...

As gene therapies continue to advance, the demand for scalable, reproducible, and efficient potency assays is rapidly increasing—especially for adeno-associated virus (AAV) vectors. Accurate ...

Circio Holding announces, it is presenting new and confirmatory in vivo data for its circVec-AAV expression platform. The in vivo results show, for the first time, up to 50-fold enhanced AAV-circVec ...

Contemporary AD systemic selection remains largely preference- and logistics-driven, despite modest EASI-75/EASI-90 response rates with Th2 biologics and JAK inhibitors at 12–16 weeks. The GEP-497 ...

Engineered oncolytic bacteria have emerged as a promising therapeutic platform for precision cancer treatment, offering tumor-specific colonization, immune activation, and controllable therapeutic ...

Recent estimates of chronic pain prevalence in the United States indicate that more than 50 million adults (20.5 percent) report experiencing pain on most days or every day (Yong, Mullins, and ...